Inhibition of nucleotide biosynthesis potentiates the antifungal activity of Amphotericin B

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Banerjee, Dithi ^a   Burkard, Lauren ^a   Panepinto, John C ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; GUANINE; MYCOPHENOLIC ACID; PURINE; PYRIMIDINE; URACIL; URIDINE;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLUS FUMIGATUS; AUXOTROPHY; CANDIDA ALBICANS; CONTROLLED STUDY; CRYPTOCOCCUS NEOFORMANS; DRUG DETERMINATION; DRUG POTENTIATION; EPSILOMETER TEST; FUNGAL GENE; FUNGAL STRAIN; GENE MUTATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEOTIDE METABOLISM; URA5 GENE;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; ASPERGILLUS FUMIGATUS; CANDIDA ALBICANS; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; FLUCYTOSINE; HIV INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOPHENOLIC ACID; NUCLEOTIDES;

EID: 84900450419     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0087246     Document Type: Article

References (46)

1. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, et al. (2009) Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 23: 525-530.
2. Thompson GR III, Cadena J, Patterson TF (2009) Overview of antifungal agents. Clin Chest Med 30: 203-215.
3. Aoun M (2000) Standard antifungal therapy in neutropenic patients. Int J Antimicrob Agents 16: 143-145.
4. Deray G (2002) Amphotericin B nephrotoxicity. J Antimicrob Chemother 49 Suppl 1: 37-41.
5. Kagan S, Ickowicz D, Shmuel M, Altschuler Y, Sionov E, et al. (2012) Toxicity mechanisms of amphotericin B and its neutralization by conjugation with arabinogalactan. Antimicrob Agents Chemother 56: 5603-5611.
6. Galmarini CM, Mackey JR, Dumontet C (2002) Nucleoside analogues and nucleobases in cancer treatment. Lancet Oncol 3: 415-424. (Pubitemid 36958272)
7. Engl T, Makarevic J, Relja B, Natsheh I, Muller I, et al. (2005) Mycophenolate mofetil modulates adhesion receptors of the beta1 integrin family on tumor cells: impact on tumor recurrence and malignancy. BMC Cancer 5: 4.
8. Leyssen P, Balzarini J, De Clercq E, Neyts J (2005) The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase. J Virol 79: 1943-1947. (Pubitemid 40459141)
9. Wang QY, Bushell S, Qing M, Xu HY, Bonavia A, et al. (2011) Inhibition of dengue virus through suppression of host pyrimidine biosynthesis. J Virol 85: 6548-6556.
10. Hyde JE (2007) Targeting purine and pyrimidine metabolism in human apicomplexan parasites. Curr Drug Targets 8: 31-47.
11. Christopherson RI, Lyons SD, Wilson PK (2002) Inhibitors of de novo nucleotide biosynthesis as drugs. Accounts of Chemical Research 35: 961-971.
12. Ittarat I, Asawamahasakda W, Bartlett MS, Smith JW, Meshnick SR (1995) Effects of Atovaquone and Other Inhibitors on Pneumocystis carinii Dihydroorotate Dehydrogenase. Antimicrob Agents Chemother 39: 325-328.
13. Cassera MB, Zhang Y, Hazleton KZ, Schramm VL (2011) Purine and Pyrimidine Pathways as Targets in Plasmodium falciparum. Current Topics in Medicinal Chemistry 11: 2103-2115.
14. Vermes A, Guchelaar HJ, Dankert J (2000) Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother 46: 171-179. (Pubitemid 30639285)
15. Pfaller MA, Messer SA, Boyken L, Huynh H, Hollis RJ, et al. (2002) In vitro activities of 5-fluorocytosine against 8,803 clinical isolates of Candida spp.: global assessment of primary resistance using National Committee for Clinical Laboratory Standards susceptibility testing methods. Antimicrob Agents Chemother 46: 3518-3521. (Pubitemid 35192920)
16. Brouwer AE, Rajanuwong A, Chierakul W, Griffin GE, Larsen RA, et al. (2004) Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet 363: 1764-1767. (Pubitemid 38698379)
17. Dromer F, Bernede-Bauduin C, Guillemot D, Lortholary O (2008) Major role for amphotericin B-flucytosine combination in severe cryptococcosis. PLoS One 3: e2870.
18. Ghannoum MA, Fu Y, Ibrahim AS, Mortara LA, Shafiq MC, et al. (1995) In vitro determination of optimal antifungal combinations against Cryptococcus neoformans and Candida albicans. Antimicrob Agents Chemother 39: 2459-2465.
19. Bennett JE, Dismukes WE, Duma RJ, Medoff G, Sande MA, et al. (1979) A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. N Engl J Med 301: 126-131. (Pubitemid 10225854)
20. Sneller MR, Hariri A, Sorenson WG, Larsh HW (1977) Comparative study of trichothecin, amphotericin B, and 5-fluorocytosine against Cryptococcus neoformans in vitro and in vivo. Antimicrob Agents Chemother 12: 390-394. (Pubitemid 8170517)
21. Schwarz P, Dromer F, Lortholary O, Dannaoui E (2003) In vitro interaction of flucytosine with conventional and new antifungals against Cryptococcus neoformans clinical isolates. Antimicrob Agents Chemother 47: 3361-3364. (Pubitemid 37229607)
22. Varma A, Edman JC, Kwon-Chung KJ (1992) Molecular and genetic analysis of URA5 transformants of Cryptococcus neoformans. Infect Immun 60: 1101-1108.
23. Morrow CA, Valkov E, Stamp A, Chow EW, Lee IR, et al. (2012) De novo GTP biosynthesis is critical for virulence of the fungal pathogen Cryptococcus neoformans. PLoS Pathog 8: e1002957.
24. Edman JC, Kwon-Chung KJ (1990) Isolation of the URA5 gene from Cryptococcus neoformans var. neoformans and its use as a selective marker for transformation. Mol Cell Biol 10: 4538-4544.
25. Balish E (2009) A URA3 null mutant of Candida albicans (CAI-4) causes orooesophageal and gastric candidiasis and is lethal for gnotobiotic, transgenic mice (Tgepsilon26) that are deficient in both natural killer and T cells. J Med Microbiol 58: 290-295.
26. White RL, Burgess DS, Manduru M, Bosso JA (1996) Comparison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and E test. Antimicrob Agents Chemother 40: 1914-1918. (Pubitemid 26277815)
27. Berenbaum MC (1978) A method for testing for synergy with any number of agents. J Infect Dis 137: 122-130.
28. Panepinto JC, Komperda KW, Hacham M, Shin S, Liu X, et al. (2007) Binding of serum mannan binding lectin to a cell integrity-defective Cryptococcus neoformans ccr4D mutant. Infect Immun 75: 4769-4779. (Pubitemid 47502146)
29. Zaragoza O, Casadevall A (2004) Experimental modulation of capsule size in Cryptococcus neoformans. Biol Proced Online 6: 10-15.
30. Denis-Duphil M (1989) Pyrimidine biosynthesis in Saccharomyces cerevisiae: the ura2 cluster gene, its multifunctional enzyme product, and other structural or regulatory genes involved in de novo UMP synthesis. Biochem Cell Biol 67: 612-631.
31. Doering TL (2009) How sweet it is! Cell wall biogenesis and polysaccharide capsule formation in Cryptococcus neoformans. Annu Rev Microbiol 63: 223-247.
32. Moyrand F, Janbon G (2004) UGD1, encoding the Cryptococcus neoformans UDP-glucose dehydrogenase, is essential for growth at 37 degrees C and for capsule biosynthesis. Eukaryot Cell 3: 1601-1608. (Pubitemid 40025117)
33. Moyrand F, Klaproth B, Himmelreich U, Dromer F, Janbon G (2002) Isolation and characterization of capsule structure mutant strains of Cryptococcus neoformans. Mol Microbiol 45: 837-849. (Pubitemid 34989189)
34. Phillips AJ, Sudbery I, Ramsdale M (2003) Apoptosis induced by environmental stresses and amphotericin B in Candida albicans. Proc Natl Acad Sci U S A 100: 14327-14332. (Pubitemid 37499236)
35. Chesney PJ, Teets KC, Mulvihill JJ, Salit IE, Marks MI (1976) Successful treatment of Candida meningitis with amphotericin B and 5-fluorocytosine in combination. J Pediatr 89: 1017-1019. (Pubitemid 8004240)
36. Titsworth E, Grunberg E (1973) Chemotherapeutic activity of 5-fluorocytosine and amphotericin B against Candida albicans in mice. Antimicrob Agents Chemother 4: 306-308.
37. Steinbach WJ, Stevens DA, Denning DW (2003) Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001. Clin Infect Dis 37 Suppl 3: S188-224. (Pubitemid 37260462)
38. Latge JP (1999) Aspergillus fumigatus and aspergillosis. Clin Microbiol Rev 12: 310-350.
39. Walsh TJ, Groll AH (1999) Emerging fungal pathogens: evolving challenges to immunocompromised patients for the twenty-first century. Transpl Infect Dis 1: 247-261.
40. Lauer BA, Reller LB, Schroter GP (1978) Susceptibility of Aspergillus to 5-fluorocytosine and amphotericin B alone and in combination. J Antimicrob Chemother 4: 375-380. (Pubitemid 9001335)
41. Hughes CE, Harris C, Moody JA, Peterson LR, Gerding DN (1984) In vitro activities of amphotericin B in combination with four antifungal agents and rifampin against Aspergillus spp. Antimicrob Agents Chemother 25: 560-562. (Pubitemid 14101140)
42. Odds FC (1982) Interactions among Amphotericin-B, 5-Fluorocytosine, Ketoconazole, and Miconazole against Pathogenic Fungi Invitro. Antimicrob Agents Chemother 22: 763-770.
43. Andriole VT (1999) The 1998 Garrod lecture. Current and future antifungal therapy: new targets for antifungal agents. J Antimicrob Chemother 44: 151-162.
44. DiDomenico B (1999) Novel antifungal drugs. Current Opinion in Microbiology 2: 509-515.
45. Low CY, Rotstein C (2011) Emerging fungal infections in immunocompromised patients. F1000 Med Rep 3: 14.
46. Miceli MH, Diaz JA, Lee SA (2011) Emerging opportunistic yeast infections. Lancet Infect Dis 11: 142-151.